Pioglitazone, a thiazolidinedione used to reduce insulin resistance in patients with type 2 diabetes, was well tolerated in a pilot study of nondiabetic patients with probable Alzheimer’s disease, providing support for continuing studies of this class of drugs in early stages of Alzheimer’s, according to a report published online on Sept. 13 in the Archives of Neurology.
